🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “Lianyungang” Clear

  1. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  2. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  4. Nintedanib,Dextromethorphan

    The First People's Hospital of Lianyungang

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  5. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  6. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  7. OMC and pseudo-SDT

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other completed

    1 trial

  8. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  9. Octacalcium phosphate

    The First People's Hospital of Lianyungang

    Tooth Extraction

    phase 2 other completed

    1 trial

  10. Olverembatinib

    The First People's Hospital of Lianyungang

    Philadelphia-Positive ALL

    phase 2 small molecule active

    1 trial

  11. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  12. Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy

    The First People's Hospital of Lianyungang

    Psoriasis

    phase 2 small molecule active

    1 trial

  13. Orelabrutinib

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  14. Orelabrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  15. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  16. Orelabrutinib

    The First People's Hospital of Lianyungang

    MALT Lymphoma

    phase 2 small molecule active

    1 trial

  17. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  18. PC-SOD

    The First People's Hospital of Lianyungang

    Myocardial Reperfusion Injury

    phase 2 small molecule active

    1 trial

  19. PCAR-019 (anti-CD19 CAR-T cells)

    The First People's Hospital of Lianyungang

    Acute Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  20. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  21. PD-1 antibody Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancers

    phase 2 small molecule active

    1 trial

  22. PD-1 inhibitor

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    phase 2 small molecule active

    1 trial

  23. PD-1/CTLA-4 Dual Functional Antibody

    The First People's Hospital of Lianyungang

    Bile Duct Carcinoma

    phase 2 small molecule active

    1 trial

  24. PEG-somatropin

    The First People's Hospital of Lianyungang

    Short Stature Children Born Small for Gestational Age (SGA)

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources